Compare Stocks: BBOT, IMNM, RARE, and NRIX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBOT BridgeBio Oncology Therapeutics	$8.78 -2.0%	$8.18	$7.00 ▼ $14.87	$703.34M	0.36	365,329 shs	186,961 shs
IMNM Immunome	$25.82 +1.2%	$21.36	$8.66 ▼ $27.65	$2.92B	2.08	1.39 million shs	832,002 shs
NRIX Nurix Therapeutics	$25.22 +0.4%	$20.95	$8.19 ▼ $25.49	$2.62B	1.79	1.50 million shs	618,075 shs
RARE Ultragenyx Pharmaceutical	$25.82 +3.6%	$27.80	$18.29 ▼ $39.89	$2.54B	0.35	2.23 million shs	1.93 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBOT BridgeBio Oncology Therapeutics	+1.01%	+8.87%	+6.54%	+13.99%	+895,999,900.00%
IMNM Immunome	+1.84%	+10.43%	+6.78%	+15.01%	+135.21%
NRIX Nurix Therapeutics	+1.74%	+6.44%	+4.49%	+54.30%	+122.10%
RARE Ultragenyx Pharmaceutical	-3.41%	-0.28%	-26.02%	-4.59%	-13.80%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBOT BridgeBio Oncology Therapeutics	$8.78 -2.0%	$8.18	$7.00 ▼ $14.87	$703.34M	0.36	365,329 shs	186,961 shs
IMNM Immunome	$25.82 +1.2%	$21.36	$8.66 ▼ $27.65	$2.92B	2.08	1.39 million shs	832,002 shs
NRIX Nurix Therapeutics	$25.22 +0.4%	$20.95	$8.19 ▼ $25.49	$2.62B	1.79	1.50 million shs	618,075 shs
RARE Ultragenyx Pharmaceutical	$25.82 +3.6%	$27.80	$18.29 ▼ $39.89	$2.54B	0.35	2.23 million shs	1.93 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBOT BridgeBio Oncology Therapeutics	+1.01%	+8.87%	+6.54%	+13.99%	+895,999,900.00%
IMNM Immunome	+1.84%	+10.43%	+6.78%	+15.01%	+135.21%
NRIX Nurix Therapeutics	+1.74%	+6.44%	+4.49%	+54.30%	+122.10%
RARE Ultragenyx Pharmaceutical	-3.41%	-0.28%	-26.02%	-4.59%	-13.80%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBOT BridgeBio Oncology Therapeutics	2.75	Moderate Buy	$24.80	182.46% Upside
IMNM Immunome	2.86	Moderate Buy	$33.17	28.45% Upside
NRIX Nurix Therapeutics	2.80	Moderate Buy	$34.00	34.81% Upside
RARE Ultragenyx Pharmaceutical	2.83	Moderate Buy	$57.82	123.95% Upside

Current Analyst Ratings Breakdown

Latest BBOT, IMNM, RARE, and NRIX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/5/2026	RARE Ultragenyx Pharmaceutical	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$47.00 ➝ $45.00
8/4/2026	NRIX Nurix Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$34.00
8/4/2026	RARE Ultragenyx Pharmaceutical	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$43.00 ➝ $35.00
7/28/2026	NRIX Nurix Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$36.00 ➝ $38.00
7/22/2026	NRIX Nurix Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$23.00 ➝ $31.00
7/21/2026	IMNM Immunome	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$31.00
7/17/2026	IMNM Immunome	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	NRIX Nurix Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/13/2026	NRIX Nurix Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$30.00 ➝ $34.00
7/10/2026	NRIX Nurix Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $34.00
7/10/2026	NRIX Nurix Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $34.00

(Data available from 8/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBOT BridgeBio Oncology Therapeutics	N/A	N/A	N/A	N/A	$5.14 per share	N/A
IMNM Immunome	$4.02M	728.30	N/A	N/A	$5.75 per share	4.49
NRIX Nurix Therapeutics	$36.77M	71.19	N/A	N/A	$5.29 per share	4.77
RARE Ultragenyx Pharmaceutical	$673M	3.78	N/A	N/A	($0.83) per share	-31.11

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBOT BridgeBio Oncology Therapeutics	-$134.04M	-$2.05	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	-$212.39M	-$2.38	N/A	N/A	N/A	N/A	-51.15%	-47.32%	N/A
NRIX Nurix Therapeutics	-$264.46M	-$3.45	N/A	N/A	N/A	-928.44%	-76.09%	-57.31%	10/8/2026 (Estimated)
RARE Ultragenyx Pharmaceutical	-$575M	-$5.84	N/A	N/A	N/A	-81.79%	-1,024.42%	-43.78%	N/A

Latest BBOT, IMNM, RARE, and NRIX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/4/2026	Q2 2026	RARE Ultragenyx Pharmaceutical	-$1.22	-$0.90	+$0.32	-$0.90	$183.08 million	$214.00 million
7/9/2026	Q2 2026	NRIX Nurix Therapeutics	-$0.73	-$0.81	-$0.08	-$0.81	$15.29 million	$9.04 million
5/12/2026	Q1 2026	BBOT BridgeBio Oncology Therapeutics	N/A	-$526.11	N/A	-$526.11	N/A	N/A
5/12/2026	Q1 2026	IMNM Immunome	-$0.60	-$0.48	+$0.12	-$0.48	$0.22 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBOT BridgeBio Oncology Therapeutics	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBOT BridgeBio Oncology Therapeutics	N/A	6.16	6.16
IMNM Immunome	N/A	21.68	21.68
NRIX Nurix Therapeutics	N/A	6.34	6.34
RARE Ultragenyx Pharmaceutical	N/A	2.02	1.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBOT BridgeBio Oncology Therapeutics	54.89%
IMNM Immunome	44.58%
NRIX Nurix Therapeutics	N/A
RARE Ultragenyx Pharmaceutical	97.67%

Insider Ownership

Company	Insider Ownership
BBOT BridgeBio Oncology Therapeutics	24.40%
IMNM Immunome	7.21%
NRIX Nurix Therapeutics	6.70%
RARE Ultragenyx Pharmaceutical	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBOT BridgeBio Oncology Therapeutics	N/A	80.11 million	60.56 million	N/A
IMNM Immunome	40	113.25 million	105.09 million	Optionable
NRIX Nurix Therapeutics	300	103.78 million	96.83 million	Optionable
RARE Ultragenyx Pharmaceutical	1,371	98.49 million	93.37 million	Optionable

BBOT, IMNM, RARE, and NRIX Headlines

Recent News About These Companies

Ultragenyx Pharmaceutical Q2 Loss Narrows as Revenue Rises; 2026 Revenue Guidance Reaffirmed

August 6 at 12:25 PM | finance.yahoo.com

Guggenheim Has Lowered Expectations for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price

August 6 at 2:30 AM | americanbankingnews.com

Ultragenyx's Q2 Earnings Beat Estimates, Revenues Jump Y/Y

August 5 at 12:51 PM | zacks.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Cut to $45.00 by Analysts at Wells Fargo & Company

August 5 at 11:23 AM | marketbeat.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap Up on Strong Earnings

August 5 at 10:19 AM | marketbeat.com

Ultragenyx Pharmaceutical Inc. (RARE) Q2 2026 Earnings Call Transcript

August 5 at 6:00 AM | seekingalpha.com

Ultragenyx Pharmaceutical Q2 Earnings Call Highlights

August 4 at 10:02 PM | marketbeat.com

Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

August 4 at 8:31 PM | zacks.com

Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates

August 4 at 8:02 PM | zacks.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Posts Earnings Results, Beats Estimates By $0.32 EPS

August 4 at 7:40 PM | marketbeat.com

Ultragenyx: Q2 Earnings Snapshot

August 4 at 6:33 PM | aol.comA

Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update

August 4 at 4:05 PM | globenewswire.com

Guggenheim Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price

August 4 at 8:11 AM | marketbeat.com

The Manufacturers Life Insurance Company Boosts Holdings in Ultragenyx Pharmaceutical Inc. $RARE

August 4 at 5:03 AM | marketbeat.com

Bank of New York Mellon Corp Acquires 42,419 Shares of Ultragenyx Pharmaceutical Inc. $RARE

August 4 at 3:20 AM | marketbeat.com

Ultragenyx Pharmaceutical (RARE) Expected to Post Quarterly Earnings on Tuesday

August 3 at 2:56 AM | americanbankingnews.com

Ultragenyx Pharmaceutical Inc. $RARE Holdings Raised by Renaissance Technologies LLC

August 2, 2026 | marketbeat.com

Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update

July 28, 2026 | globenewswire.com

Earnings Preview: Ultragenyx (RARE) Q2 Earnings Expected to Decline

July 28, 2026 | zacks.com

Ultragenyx Pharmaceutical (RARE) to Release Earnings on Tuesday

July 28, 2026 | marketbeat.com

Rock Springs Capital Management LP Sells 48,468 Shares of Ultragenyx Pharmaceutical Inc. $RARE

July 28, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BBOT, IMNM, RARE, and NRIX Company Descriptions

BridgeBio Oncology Therapeutics NASDAQ:BBOT

$8.78 -0.18 (-2.01%)

Closing price 04:00 PM Eastern

Extended Trading

$8.81 +0.03 (+0.34%)

As of 04:10 PM Eastern

We are a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Throughout this prospectus, we will refer to this as our initial business combination. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any potential business combination target with respect to an initial business combination with us. While we may pursue a business combination target in any business or industry, we intend to focus on healthcare or healthcare related industries, which can benefit from the expertise and capabilities of our management team in order to create long-term shareholder value. Our sponsor is an affiliate of Cormorant, a leading life sciences focused investment firm with over $2 billion in assets under management as of December 31, 2022. Our Chairperson and Chief Executive Officer, Bihua Chen, founded Cormorant and is the managing member of Cormorant. Since its inception in 2013, Cormorant has focused on the healthcare industry and invests, throughout their growth cycle, in companies that discover and develop therapeutic drugs or medical technology. Cormorant is an active life-science investor with investments in over 100 privately held, life science-focused companies over this period. Of these investments, over 50 have completed initial public offerings. Notable successes include Prometheus Biosciences, Inc., Turning Point Therapeutics, Inc., and MyoKardia, Inc., each of which has been acquired for more than $4 billion. Other notable successes include BridgeBio Pharma Inc. and Apellis Pharmaceuticals Inc., each of which is a public company with a market capitalization greater than $1 billion. Our executive offices are located at 200 Clarendon Street, 52nd Floor, Boston, MA.

Immunome NASDAQ:IMNM

$25.82 +0.30 (+1.18%)

Closing price 04:00 PM Eastern

Extended Trading

$25.82 0.00 (0.00%)

As of 06:06 PM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Nurix Therapeutics NASDAQ:NRIX

$25.22 +0.10 (+0.40%)

Closing price 04:00 PM Eastern

Extended Trading

$25.00 -0.22 (-0.87%)

As of 06:33 PM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Ultragenyx Pharmaceutical NASDAQ:RARE

$25.82 +0.89 (+3.57%)

Closing price 04:00 PM Eastern

Extended Trading

$26.11 +0.29 (+1.12%)

As of 06:40 PM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BBOT, IMNM, RARE, and NRIX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BBOT, IMNM, RARE, and NRIX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BBOT, IMNM, RARE, and NRIX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BBOT, IMNM, RARE, and NRIX Company Descriptions

BridgeBio Oncology Therapeutics NASDAQ:BBOT

Immunome NASDAQ:IMNM

Nurix Therapeutics NASDAQ:NRIX

Ultragenyx Pharmaceutical NASDAQ:RARE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BBOT, IMNM, RARE, and NRIX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BBOT, IMNM, RARE, and NRIX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BBOT, IMNM, RARE, and NRIX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BBOT, IMNM, RARE, and NRIX Company Descriptions

BridgeBio Oncology Therapeutics NASDAQ:BBOT

Immunome NASDAQ:IMNM

Nurix Therapeutics NASDAQ:NRIX

Ultragenyx Pharmaceutical NASDAQ:RARE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools